2. Disease Areas
  3. Inflammation or Immune System Disease
  4. Autoimmune Disease
  5. Inflammatory Bowel Disease

Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) is a chronic, recurrent condition characterized by inflammation of the gastrointestinal tract, primarily encompassing Crohn's disease and ulcerative colitis. Crohn's disease can affect any segment of the digestive tract from the mouth to the anus, often involving transmural inflammation and skip lesions, while ulcerative colitis is limited to the colon and rectum, with continuous mucosal inflammation. Common symptoms include abdominal pain, cramping, diarrhea (often with blood or mucus), weight loss, fatigue, loss of appetite, and nausea, resulting from chronic inflammation and impaired nutrient absorption. The exact cause remains unknown, but IBD is believed to arise from an abnormal immune response to intestinal microbiota in genetically susceptible individuals. Although there is no cure, treatment aims to control symptoms and induce remission through medications such as aminosalicylates, corticosteroids, immunomodulators, and biologics, alongside lifestyle modifications including dietary changes and stress management. Early diagnosis and ongoing management are critical to preventing complications and improving quality of life, as IBD is a lifelong condition with variable clinical course and symptom patterns among individuals.

Inflammatory Bowel Disease (34):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117287
    Deucravacitinib 1609392-27-9 99.93%
    Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
    Deucravacitinib
  • HY-108749
    Olive oil 8001-25-0
    Olive oil (Cropure OL) is an oleaginous compound found in the fruit of the Olea europaea tree. Olive oil contains many phenolic components and exerts antioxidant activity. Olive oil exhibits hydroxyl radical scavenging, platelet aggregation inhibition and xanthine oxidase inhibitory activity. Olive oil can promote wound healing and relieve inflammation. Olive oil can be used for the research of inflammation, cancer, metabolic and cardiovascular disease, such as diabetic foot ulcers and inflammatory bowel disease.
    Olive oil
  • HY-P990876
    Afimkibart 2911580-96-4 99.59%
    Afimkibart (PF-06480605; RVT-3101) is a fully human monoclonal antibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart neutralizes active trimeric TL1A, blocks TL1A-induced signaling pathways. Afimkibart inhibits NF-κB activation and IFN-γ production. Afimkibart can be used for the research of inflammatory bowel disease.
    Afimkibart
  • HY-113402
    Gamma-glutamylcysteine 636-58-8 98.53%
    Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
    Gamma-glutamylcysteine
  • HY-113402A
    Gamma-glutamylcysteine TFA 283159-88-6
    Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
    Gamma-glutamylcysteine TFA
  • HY-W740611
    Trihydroxycoprostane 547-96-6
    Trihydroxycoprostane (THCP) is a polyhydroxysterane compound with a 5β configuration. ITrihydroxycoprostane acts as a key intermediate in the biosynthesis of bile acids from cholesterol and also serves as an important sterol metabolite generated by host-gut microbiota interactions. Trihydroxycoprostane can be used for mechanistic studies of diseases such as non-alcoholic fatty liver disease, inflammatory bowel disease, and bile acid metabolism disorders.
    Trihydroxycoprostane
  • HY-186079
    Deethyl-emvistegrast
    Deethyl-emvistegrast is a quinoline derivative and also a α4β7 integrin inhibitor. Deethyl-emvistegrast is the hydrolytic product of Emvistegrast (HY-177080). Deethyl-emvistegrast modulates inflammatory pathways. Deethyl-emvistegrast can be used in research related to inflammatory bowel disease (Crohn's disease and ulcerative colitis).
    Deethyl-emvistegrast
  • HY-177080B
    Emvistegrast axial isomer
    Emvistegrast (GS-1427) axial isomer is an axial isomer of Emvistegrast (HY-177080). Emvistegrast axial isomer is an integrin α4β7 inhibtor.
    Emvistegrast axial isomer
  • HY-70005
    CPA inhibitor 223532-02-3 99.78%
    CPA inhibitor (Compound 5) (Carboxypeptidase inhibitor) is an orally active competitive carboxypeptidase A (CPA) inhibitor with a Ki value of 0.32 μM. CPA inhibitor blocks the activity of carboxypeptidase A3 (CPA3). CPA activator activates the Wnt/Lrp6/β-catenin signaling pathway. CPA inhibitor reduces epithelial damage. CPA inhibitor is applicable to research related to inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
    CPA inhibitor
  • HY-13769A
    TPT-260 Dihydrochloride 2076-91-7 98.0%
    TPT-260 Dihydrochloride (NSC55712), a thiophene thiourea derivative, is a retromer complex stabilizer against thermal denaturation (Kd = ~5 µM). TPT-260 Dihydrochloride increases the levels of retromer proteins, shifts amyloid-precursor protein (APP) away from the endosome, and decreases the pathogenic processing of APP. TPT-260 Dihydrochloride inhibits TLR4 upregulation, IKKβ phosphorylation, NF-κB p65 nuclear translocation, and NLRP3 inflammasome formation. TPT-260 Dihydrochloride improves retromer-mediated cargo trafficking, reduces brain infarct area, and decreases amyloid plaque deposition. TPT-260 Dihydrochloride exhibits minimal cytotoxicity to primary microglia at tested concentrations. TPT-260 Dihydrochloride can be used for the research of inflammatory bowel disease, ischemic stroke and Alzheimer's disease.
    TPT-260 Dihydrochloride
  • HY-N7114A
    Chloramphenicol succinate sodium 982-57-0 ≥98.0%
    Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease.
    Chloramphenicol succinate sodium
  • HY-114354
    BODIPY FL alkyne 302795-84-2 98.60%
    BODIPY (BOD) FL alkyne is an alkyne-containing BODIPY fluorophore derivative. BODIPY FL alkyne is a bioorthogonal labeling reagent with low toxicity and extremely low non-specific reactivity, and it is widely used in fluorescent bioimaging. BODIPY FL alkyne specifically labels azide groups on intracellular glycoconjugates mainly via strain-promoted azide-alkyne cycloaddition (SPAAC), or mediates site-specific conjugation with proteins such as IL-33, and supports positive cross-linking with other probes (e.g., DBCO-SCy5) for dual labeling. With the advantages of high specificity and low background interference, BODIPY FL alkyne can be used in the research of related diseases such as asthma, atopic dermatitis and inflammatory bowel disease.
    BODIPY FL alkyne
  • HY-147105
    LRH-1 agonist-2 2244781-29-9 98.58%
    LRH-1 agonist-2 (Compound 6N) is a selective, full LRH-1 agonist with an EC50 of 15.7 nM. LRH-1 agonist-2 directly interacts with the Thr352 and His390 residues in the LRH-1 binding pocket, promotes allosteric signaling to the activation function surface (AFS), stabilizes the AFS and enhances coactivator recruitment. LRH-1 agonist-2 induces the anti-inflammatory cytokine IL-10, and reduces the pro-inflammatory cytokines IL-1β and TNFα. LRH-1 modulator-1 exerts anti-inflammatory effects in intestinal organoids. LRH-1 modulator-1 can be used in studies related to inflammatory bowel disease.
    LRH-1 agonist-2
  • HY-163102
    IA-14069 2271216-04-5 99.93%
    IA-14069 is an orally active tumor necrosis factor-α (TNF-α) inhibitor. IA-14069 binds directly to TNF-α and TNF-α-triggered signaling (p-IκBα and NF-κB p65) activities. Additionally, IA-14069 exerts a suppressive effect on Dextran sodium sulfate (HY-116282C) (DSS)-induced colitis. IA-14069 can be used for the research of Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).
    IA-14069
  • HY-162588
    MC-ND-18 3081572-53-1
    MC-ND-18 is an ATTEC degrader that degrades NLRP3 via the Autophagy pathway, with a DC50 of 125.5 nM in THP-1 cells. MC-ND-18 exhibits anti-inflammatory activity in a DSS-induced mouse model of colitis. MC-ND-18 can be used for research on inflammatory bowel disease. MC-ND-18 consists of an NLRP3 inhibitor (HY-156121), a linker (HY-W018745), and an LC3 ligand.
    MC-ND-18
  • HY-W750419
    cis-9-Hexadecenoylcarnitine inner salt 329321-94-0
    cis-9-Hexadecenoylcarnitine inner salt (Palmitoleoylcarnitine (C16:1)) is a long-chain acylcarnitine controlling fatty acid metabolism and mitochondrial function. cis-9-Hexadecenoylcarnitine inner salt accumulates in colorectal cancer cells. cis-9-Hexadecenoylcarnitine inner salt exists in plants and mediates lipid anabolic development. cis-9-Hexadecenoylcarnitine inner salt acts as a metabolic marker for type 1 diabetes and inflammatory bowel disease plasma. cis-9-Hexadecenoylcarnitine inner salt can be used for research on diabetes, metabolism, and inflammatory bowel disease.
    cis-9-Hexadecenoylcarnitine inner salt
  • HY-E71367
    Bromelain (USP)
    Bromelain USP is an orally active proteolytic agent. Bromelain USP converts plasminogen to plasmin to support fibrinolysis, cleaves CD44 adhesion molecules from cell surfaces, and diminishes uPAR expression and uPA activity. Bromelain USP can inhibit the activity of a variety of fungi and bacteria. Bromelain USP can be used for the research of angina pectoris, atherosclerotic disease, fungal infections, bacterial infections, chronic inflammatory bowel disease, and cancer.
    Bromelain (USP)
  • HY-183573
    PTPRO-IN-1
    PTPRO-IN-1 is a selective, orally active PTPRO inhibitor with an IC50 of 0.16 μM. PTPRO-IN-1 exhibits IC50 values of 2.4 μM, 2.33 μM and 2.13 μM against PTPN22, PTP1B and PTPRT, respectively, and shows almost no inhibitory activity against STEP/SSH2. PTPRO-IN-1 inhibits the TLR4/NF-κB signaling pathway in macrophages, ameliorates colonic pathological conditions and suppresses the secretion of pro-inflammatory cytokines by T cells. PTPRO-IN-1 can be used for the research of inflammatory bowel disease.
    PTPRO-IN-1
  • HY-182503
    GP515 144928-48-3
    GP515 is a potent and selective adenosine kinase inhibitor with a human IC50 of 4 nM. GP515 exerts tissue protective effects, produces long-lasting hepatic microcirculation effects after hemorrhagic shock, and induces dose- and time-related VEGF mRNA and protein expression in normoxic rat myocardial myoblasts, with additive VEGF increases during mild hypoxia and no effect during severe hypoxia. GP515 suppresses IFNγ synthesis and CD69 expression in DSS-induced colitis. GP515 also shows a dose-dependent suppression of TNF-α production with an IC50 of 80 μM and can be reversed in the presence of the cAMP antagonist (Rp)-cAMPS. Combinations of GP515 with either adenosine or rolipram led to an additive inhibition of TNF-α synthesis. GP515 can be used for the research of hemorrhagic shock.
    GP515
  • HY-186079A
    (S)-Deethyl-emvistegrast
    (S)-Deethyl-emvistegrast is the S-enantiomer of Deethyl-emvistegrast (HY-186079). Deethyl-emvistegrast is a quinoline derivative and also a α4β7 integrin inhibitor. It acts as the hydrolysis product of Emvistegrast (HY-177080). Deethyl-emvistegrast modulates inflammatory pathways and can be used in research related to inflammatory bowel diseases (Crohn's disease and ulcerative colitis).
    (S)-Deethyl-emvistegrast